Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research

Comparative effectiveness research (CER) has been heralded as a way to reduce health-care costs by determining which treatments provide the most benefit for the largest number of patients. This report warns that by choosing "winners and losers," CER drug trials may leave patients who best respond to the "losing" drug without coverage.

The report, conducted by researchers Tomas Philipson and Eric Sun of the Manhattan Institute's Project FDA, examines a CER trial for antipsychotic drugs in the Medicaid program and finds that applying restrictive reimbursement for "losing" drugs could actually reduce patient health and increase health-care costs. By limiting coverage for more expensive drugs that benefit patients outside the average, the authors find that worsened patient health would increase health-care costs by $1.3 billion, outweighing the Medicaid savings.

Dr. Philipson authored a related paper on this topic, "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," that was published in the Journal of Health Economics website.

Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
Blog Post

#TBT: Medicaid Expansion & Historical Data

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, Quintiles Study Tests Tools to Evaluate Quality of Observational Research in Comparative Effectiveness Studies

(Washington, DC, February 25, 2014)—With the growing demand for information about comparative effectiveness and questions about the quality of...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Statement on Appointment of PCORI Board Chair

Washington, DC, September 19, 2013—The National Pharmaceutical Council (NPC) today released the following statement regarding the Government...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Use of Big and Real-World Data by Pharma: More than Data Warehousing

Real-world data—a subset of big data—is clinical data used for decision-making that did not come from a clinical trial. According to Aaron Galaznik,...
YouTube Videos

Engaging Patients in Research

National Pharmaceutical Council President Dan Leonard explains why it's important to include patients throughout the research process. He says that...
YouTube Videos

Patient Input on What Makes Comparative Effectiveness Research Useful

Myrl Weinberg, chief executive officer of the National Health Council, says that many patients are still concerned about how comparative...
Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
Blog Post

#TBT: Medicaid Expansion & Historical Data

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...

Research

  •  
  • 1 of 51
  • >

Commentary & Testimony